New real-world Wegovy findings offer a useful view of changes in weight and liver blood tests among adults with metabolic dysfunction-associated steatohepatitis, or MASH. They do not settle which medicine best protects the liver over time.
In a November 6 announcement, Novo Nordisk reported two retrospective studies presented at The Liver Meeting 2026. Both examined the weekly 2.4 mg semaglutide injection. For readers following weight-management treatment, the key question is how these routine-care observations fit beside evidence that directly measured liver tissue.
Two studies, two different comparisons
PLATINUM-Truveta compared 2,873 adults starting semaglutide with 2,285 starting resmetirom. RHODIUM-2 compared 2,479 semaglutide initiators with 70,702 adults who did not initiate semaglutide. Both used electronic medical records from US health systems covering June 2021 through March 2026, according to the sponsor’s study descriptions.
Those are cohort totals, not confirmed numbers with paired measurements for every outcome. The studies excluded cirrhosis and assessed people with available follow-up data who met treatment-persistence requirements. Their populations should not be treated as interchangeable with everyone using a weight-loss medicine, or assumed to consist entirely of people without diabetes.
What the six-month comparison found
In PLATINUM-Truveta, the sponsor reported the following weighted mean changes from baseline at six months. Negative values mean a reduction. The dose identifies the studied regimen; it is not a dosing recommendation.
| Measure | Semaglutide 2.4 mg | Resmetirom |
|---|---|---|
| Body weight | −18.9 lb | −5.6 lb |
| AST liver enzyme | −10.4 U/L | −4.5 U/L |
| ALT liver enzyme | −14.8 U/L | −11.6 U/L |
| HbA1c (blood-sugar measure) | −0.38 percentage points | −0.08 percentage points |
The weight, AST and HbA1c comparisons favored semaglutide statistically. The ALT difference did not reach statistical significance (P=0.20). LDL cholesterol fell more in the resmetirom group. These details in the reported results table matter: a headline about improved markers cannot be converted into a claim that one treatment performed better on every measure.
The researchers used weighting to address measured differences between the groups. Treatment was not randomly assigned, however. Differences in the patients selected for each medicine can remain even after statistical adjustment. Our guide to randomized and real-world evidence explains why that limits causal conclusions.
Why the twelve-month result is a separate finding
The RHODIUM-2 sponsor report described mean weight changes of −30.7 lb among semaglutide initiators and −2.4 lb among noninitiators at twelve months, alongside larger liver-enzyme reductions in the semaglutide group. This was a different comparison and follow-up period, not a longer version of the resmetirom comparison. Its HbA1c figures were not adjusted, unlike the other main outcomes in the sponsor’s table.
Both analyses depend on who remained in treatment and had measurements recorded. People who stop, miss visits or lack repeat blood tests may have different experiences. The sponsor also acknowledges baseline differences, possible coding errors and unmeasured confounding. Since both studies drew on Truveta records over the same period, they should not automatically be counted as two wholly independent patient samples.
Liver enzymes and liver scarring answer different questions
The new announcement reports blood-test and metabolic changes. It does not report biopsy-confirmed fibrosis improvement or fewer liver complications. A lower enzyme result therefore cannot establish that scarring has reversed.
There is separate randomized evidence. The ESSENCE trial’s original report described a planned 72-week analysis of the first 800 participants with biopsy-defined MASH and moderate or advanced fibrosis. Fibrosis improvement without worsening steatohepatitis occurred in 36.8% with semaglutide and 22.4% with placebo. Those tissue-based results belong to that trial, not to the new observational cohorts.
Even biopsy improvement is different from proving fewer long-term complications. The ESSENCE registry lists cirrhosis-free survival over 240 weeks as a further primary outcome and currently records the study as active, not recruiting. That status is not a completed result.
What this means for a treatment conversation
The FDA-approved label already includes Wegovy injection for adults with noncirrhotic MASH and moderate-to-advanced fibrosis, consistent with stages F2–F3. This is accelerated approval, with continued approval potentially dependent on confirming clinical benefit. The November announcement is additional research news, not a new approval or an extension to all forms of fatty liver disease.
For someone discussing both weight and liver health, useful questions are: What condition and fibrosis stage are being treated? Which results will be monitored? What would count as meaningful improvement? How will side effects and treatment interruptions be handled? Our appointment guide can help organize that discussion; the semaglutide profile identifies the medicine and its evidence.
Safety remains part of the decision. The current US label describes common gastrointestinal adverse effects and a boxed thyroid C-cell tumor warning based on rodent findings, with uncertain human relevance. It contraindicates use with a personal or family history of medullary thyroid carcinoma or MEN 2. These observational results do not justify switching medicines independently.
The most useful next evidence would show endpoint-specific follow-up numbers, fuller adjustment methods, treatment discontinuations and longer-term liver outcomes. This explainer uses the sponsor’s complete announcement, the ESSENCE abstract and registry, and approved labels. Full conference posters and study manuscripts were not reviewed.



